Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 14,960 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,960 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $17.36, for a total transaction of $259,705.60. Following the transaction, the chief executive officer owned 411,861 shares in the company, valued at $7,149,906.96. This represents a 3.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Omada Health Price Performance

Omada Health stock opened at $17.64 on Friday. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92. The company’s fifty day moving average price is $15.73 and its two-hundred day moving average price is $14.78. The company has a market capitalization of $1.05 billion and a price-to-earnings ratio of -65.33.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%.The company had revenue of $78.05 million during the quarter. As a group, sell-side analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Citigroup restated an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Evercore restated an “outperform” rating and issued a $20.00 target price on shares of Omada Health in a research note on Friday, May 8th. JPMorgan Chase & Co. reduced their target price on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Finally, Morgan Stanley decreased their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, March 6th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Omada Health has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Trading of Omada Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMDA. Raymond James Financial Inc. acquired a new position in Omada Health during the 2nd quarter valued at about $32,000. Quarry LP bought a new position in shares of Omada Health in the 4th quarter valued at about $29,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Omada Health during the 4th quarter worth approximately $32,000. Inlight Wealth Management LLC acquired a new stake in shares of Omada Health during the 4th quarter worth approximately $45,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Omada Health during the third quarter worth approximately $82,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.